CD79A and rheumatoid arthritis: Furthermore, in RA patients, we found that antibodies against at least one of the 4 UH-axSpA-IgA/IgG peptides were only present in 10.0% (6/60) of RA patients compared to 25.7% of the axSpA patients from the UH-cohort (18/70) (p = 0.0244) and 15.9% of the axSpA patients from the (Bio)SPAR cohort (26/164) (p = 0.3881).